Denali Therapeutics Inc.
Symbol: DNLI
NASDAQ
20.86
USDMarkedspris i dag
-15.3834
P/E-forhold
-0.2731
PEG Ratio
2.88B
MRK Cap
- 0.00%
DIV Udbytte
Denali Therapeutics Inc. (DNLI) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4623.21 | 1034.5 | 1336.2 | 865.4 | |||||||||
balance-sheet.row.short-term-investments | 4147.99 | 907.4 | 1118.2 | 571.9 | |||||||||
balance-sheet.row.net-receivables | 9.3 | 2.7 | 5 | 1.2 | |||||||||
balance-sheet.row.inventory | -6.6 | 0 | -5 | 0 | |||||||||
balance-sheet.row.other-current-assets | 130.34 | 26.9 | 36.1 | 30.6 | |||||||||
balance-sheet.row.total-current-assets | 4756.24 | 1064.1 | 1372.3 | 897.2 | |||||||||
balance-sheet.row.property-plant-equipment-net | 283.89 | 71.6 | 74.5 | 69.6 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-investments | 12.61 | 1.6 | 1.5 | 425.4 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 53.03 | 16.5 | 11.9 | 11.9 | |||||||||
balance-sheet.row.total-non-current-assets | 349.53 | 89.8 | 87.9 | 506.9 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 5105.77 | 1153.9 | 1460.2 | 1404.2 | |||||||||
balance-sheet.row.account-payables | 21.4 | 9.5 | 2.8 | 4.8 | |||||||||
balance-sheet.row.short-term-debt | 27.59 | 7.3 | 7.3 | 5.5 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 191.16 | 45 | 53 | 58.6 | |||||||||
Deferred Revenue Non Current | 1.05 | 0 | 0.5 | 4.7 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 270.01 | 61.2 | 63.8 | 47.7 | |||||||||
balance-sheet.row.total-non-current-liabilities | 193.36 | 45 | 53.9 | 63.6 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 211.49 | 45 | 60.4 | 58.6 | |||||||||
balance-sheet.row.total-liab | 802.96 | 123 | 417.8 | 441.9 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 6.81 | 1.7 | 1.7 | 1.5 | |||||||||
balance-sheet.row.retained-earnings | -4091.1 | -1116.2 | -971 | -645 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -3.97 | 0.6 | -6.9 | -2.5 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 8391.07 | 2144.8 | 2018.6 | 1608.2 | |||||||||
balance-sheet.row.total-stockholders-equity | 4302.82 | 1031 | 1042.4 | 962.3 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5105.77 | 1153.9 | 1460.2 | 1404.2 | |||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-equity | 4302.82 | 1031 | 1042.4 | 962.3 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5105.77 | - | - | - | |||||||||
Total Investments | 4157.49 | 909 | 1118.2 | 997.4 | |||||||||
balance-sheet.row.total-debt | 218.75 | 52.2 | 60.4 | 58.6 | |||||||||
balance-sheet.row.net-debt | -256.47 | -74.9 | -157.7 | -234.9 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -145.22 | -145.2 | -326 | -290.6 | |||||||||
cash-flows.row.depreciation-and-amortization | 16.73 | 16.7 | 10.4 | 8.6 | |||||||||
cash-flows.row.deferred-income-tax | -56.28 | -2.4 | 0 | 8.7 | |||||||||
cash-flows.row.stock-based-compensation | 108.1 | 108.1 | 99.8 | 85.2 | |||||||||
cash-flows.row.change-in-working-capital | -289.93 | -289.9 | -24 | -20.4 | |||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.account-payables | 2.43 | 2.4 | 2.3 | 3.7 | |||||||||
cash-flows.row.other-working-capital | -292.36 | -292.4 | -26.3 | -24.1 | |||||||||
cash-flows.row.other-non-cash-items | 8.61 | -45.2 | -4.9 | -3 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -357.99 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -12.94 | -12.9 | -17.8 | -8.5 | |||||||||
cash-flows.row.acquisitions-net | -262.25 | 0 | 123.6 | 13.1 | |||||||||
cash-flows.row.purchases-of-investments | -1813.7 | -1813.7 | -1115 | -1422.9 | |||||||||
cash-flows.row.sales-maturities-of-investments | 2075.95 | 2075.9 | 991.5 | 1409.8 | |||||||||
cash-flows.row.other-investing-activites | 262.25 | 0 | -123.6 | -13.1 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 249.31 | 249.3 | -141.4 | -21.6 | |||||||||
cash-flows.row.debt-repayment | 0 | 0 | -3.1 | -3.7 | |||||||||
cash-flows.row.common-stock-issued | 17.82 | 17.8 | 296.2 | 19.3 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-financing-activites | 17.82 | 17.8 | 17.6 | 3.7 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 17.82 | 17.8 | 310.7 | 19.3 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | -90.86 | -90.9 | -75.4 | -213.7 | |||||||||
cash-flows.row.cash-at-end-of-period | 479.87 | 127.1 | 219.5 | 295 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 570.73 | 218 | 295 | 508.6 | |||||||||
cash-flows.row.operating-cash-flow | -357.99 | -358 | -244.7 | -211.4 | |||||||||
cash-flows.row.capital-expenditure | -12.94 | -12.9 | -17.8 | -8.5 | |||||||||
cash-flows.row.free-cash-flow | -370.93 | -370.9 | -262.5 | -219.9 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 330.53 | 330.5 | 108.5 | 48.7 | |||||||||
income-statement-row.row.cost-of-revenue | 14.92 | 16.7 | 7 | 5.6 | |||||||||
income-statement-row.row.gross-profit | 315.61 | 313.8 | 101.4 | 43.1 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 423.88 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 103.35 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -2.18 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.operating-expenses | 525.05 | 510.5 | 449.2 | 344.4 | |||||||||
income-statement-row.row.cost-and-expenses | 527.23 | 527.2 | 449.2 | 344.4 | |||||||||
income-statement-row.row.interest-income | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.interest-expense | -21.08 | 0 | 14.8 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -2.18 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.total-operating-expenses | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.interest-expense | -21.08 | 0 | 14.8 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 16.73 | 16.7 | 10.4 | 8.6 | |||||||||
income-statement-row.row.ebitda-caps | -192.31 | - | - | - | |||||||||
income-statement-row.row.operating-income | -196.7 | -196.7 | -340.7 | -295.8 | |||||||||
income-statement-row.row.income-before-tax | -145.19 | -145.2 | -326 | -291.2 | |||||||||
income-statement-row.row.income-tax-expense | -12.3 | 0 | 0 | -0.6 | |||||||||
income-statement-row.row.net-income | -145.22 | -145.2 | -326 | -290.6 |
Ofte stillede spørgsmål
Hvad er Denali Therapeutics Inc. (DNLI) samlede aktiver?
Denali Therapeutics Inc. (DNLI) samlede aktiver er 1153917000.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er 1267000.000.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.955.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er -2.683.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er -0.439.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er -0.595.
Hvad er Denali Therapeutics Inc. (DNLI) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er -145224000.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 52241000.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 510504000.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 127106000.000.